Objective To analyze the effect of three-dimensional (3D) reconstruction technique combined with anatomical segmentectomy (SA) on tumor markers, inflammatory response, blood gas indexes, and lung function in patients with non-small cell lung cancer (NSCLC). Methods From January 2022 to October 2024,74 patients with NSCLC who video-assisted thoracoscopic surgery SA (SA-VATS) in Fuyang People's Hospital were selected as the SA-VATS group, and 31 patients with NSCLC who underwent 3D three-dimensional reconstruction combined with SA-VATS were selected as the 3D group. The operation-related indexes and postoperative complications during hospitalization were statistically analyzed. The levels of serum tumor markers, inflammatory factors, and blood gas indexes before and 7 d after operation, and lung function before and 1 month after operation were compared between SA-VATS group and 3D group. Results The improvement of operation related indexes in 3D group was better than that in SA-VATS group (P<0.05). The levels of serum vascular endothelial growth factor, heat shock protein 90α, carcinoembryonic antigen, and cytokeratin 19 fragment in SA-VATS group and 3D group at 7 d after operation were lower than those before operation, and those in 3D group were lower than those the SA-VATS group (P<0.05). The levels of serum interleukin-8, interleukin-10, and tumor necrosis factor-α in the SA-VATS group and 3D group at 7 d after operation were higher than those before operation, but those in 3D group were lower than those in SA-VATS group (P<0.05). The changes of blood gas indexes in SA-VATS group and 3D group were improved at 7 d after operation, and 3D group was better than SA-VATS group (P<0.05). The pulmonary function indexes of SA-VATS group and 3D group at 1 month after operation were lower than those before operation, but those in 3D group were higher than those in SA-VATS group (P<0.05). During hospitalization after operation, there was no significant difference in the incidence of total complications between 3D group and SA-VATS group (P>0.05), but 3D group was lower than SA-VATS group. Conclusions 3D reconstruction technique combined with SA-VATS in the treatment of patients with NSCLC could effectively shorten operation time, reduce intraoperative blood loss, promote postoperative recovery of patients, reduce the level of serum tumor markers, alleviate inflammatory response, improve blood gas index and lung function, and might help to reduce the occurrence of complications.
Key words
Non-small cell lung cancer; /
/
Three-dimensional reconstruction technology; /
/
Anatomical pneumonectomy; /
/
Lung function
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Remon J, Soria J C, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy[J]. Ann Oncol, 2021, 32(12): 1637-1642. DOI: 10.1016/j.annonc.2021.08.1994.
[2] Chua TH, Chuah KL. Concordance of Cytological Specimens with Histological Tissue for Detection of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Systematic Review[J]. Acta Cytol, 2022, 66(1): 61-71. DOI: 10.1159/000519380.
[3] Kato H. Thoracoscopic anatomical segmentectomy for early-stage non-small cell lung cancer: minimally invasive surgery involving various approaches[J]. J Thorac Dis, 2023, 15(2): 242-245. DOI: 10.21037/jtd-23-3.
[4] Tosi D, Nosotti M, Bonitta G, et al. Anatomical segmentectomy versus pulmonary lobectomy for stage I non-small-cell lung cancer: patients selection and outcomes from the European Society of Thoracic Surgeons database analysis[J]. Interact Cardiovasc Thorac Surg, 2021, 32(4): 546-551. DOI: 10.1093/icvts/ivaa298.
[5] Wu YJ, Shi QT, Zhang Y, et al. Thoracoscopic segmentectomy and lobectomy assisted by three-dimensional computed-tomography bronchography and angiography for the treatment of primary lung cancer[J]. World J Clin Cases, 2021, 9(34): 10494-10506. DOI: 10.12998/wjcc.v9.i34.10494.
[6] Mohammed KK, Hassanien AE, Afify HM. A 3D image segmentation for lung cancer using V.Net architecture based deep convolutional networks[J]. J Med Eng Technol, 2021, 45(5): 337-343. DOI: 10.1080/03091902.2021.1905895.
[7] Patil SM, Kunda NK. Nisin ZP, an Antimicrobial Peptide, Induces Cell Death and Inhibits Non-Small Cell Lung Cancer (NSCLC) Progression in vitro in 2D and 3D Cell Culture[J]. Pharm Res, 2022, 39(11): 2859-2870. DOI: 10.1007/s11095-022-03220-2.
[8] Bruggeman AR, Sarkar RR, Ahn GS, et al. Split course palliative radiotherapy for advanced lung cancer with 3D planning based analysis of outcome: a retrospective review[J]. Ann Palliat Med, 2022, 11(2): 423-430. DOI: 10.21037/apm-21-1589.
[9] Oncology Branch of Chinese Medical Association, Journal of Chinese Medical Association. Clinical diagnosis and treatment guidelines of lung cancer by oncology branch of Chinese Medical Association (2021 edition) [J]. Journal of Chinese Medicine, 2021, 101(23): 1725-1757.
[10] Mennecier B, Olland A, Mascaux C, et al. Re: Two centres' experience with lung cancer resection in patients with advanced non-small-cell lung cancer following treatment with immune checkpoint inhibitors: safety and clinical outcomes[J]. Eur J Cardiothorac Surg, 2021, 60(6): 1306-1307. DOI: 10.1093/ejcts/ezab399.
[11]Kamigaichi A, Hamada A, Tsuboi M, et al. A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial)[J]. Clin Lung Cancer, 2024, 25(4): 384-388. DOI: 10.1016/j.cllc.2024.01.004.
[12]Stamatis G, Leschber G, Schwarz B, et al. Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm[J]. Lung Cancer, 2022, 172(1): 108-116. DOI: 10.1016/j.lungcan.2022.08.013.
[13]Tao J, Liang C, Yin K, et al. 3D convolutional neural network model from contrast-enhanced CT to predict spread through air spaces in non-small cell lung cancer[J]. Diagn Interv Imaging, 2022, 103(11): 535-544. DOI: 10.1016/j.diii.2022.06.002.
[14]Wu L, Lou X, Kong N, et al. Can quantitative peritumoral CT radiomics features predict the prognosis of patients with non-small cell lung cancer? A systematic review[J]. Eur Radiol, 2023, 33(3): 2105-2117. DOI: 10.1007/s00330-022-09174-8.
[15]Lee SY, Lee E, Lim JU, et al. U-Shape Pillar Strip for 3D Cell-Lumped Organoid Model (3D-COM) Mimicking Lung Cancer Hypoxia Conditions in High-Throughput Screening (HTS)[J]. Anal Chem, 2024, 96(25): 10246-10255. DOI: 10.1021/acs.analchem.4c00890.
[16]Yoon SH, Na KJ, Kang CH, et al. Remotely shared CT-derived presurgical understanding of lung cancer: A randomized trial[J]. Thorac Cancer, 2022, 13(19): 2823-2828. DOI: 10.1111/1759-7714.14637.
[17]Cui Z, Ding C, Li C, et al. Preoperative evaluation of the segmental artery by three-dimensional image reconstruction vs. thin-section multi-detector computed tomography[J]. J Thorac Dis, 2020, 12(8): 4196-4204. DOI: 10.21037/jtd-20-1014.
[18] Malmros K, Kirova N, Kotarsky H, et al. 3D cultivation of non-small-cell lung cancer cell lines using four different methods[J]. J Cancer Res Clin Oncol, 2024, 150(10): 472-472. DOI: 10.1007/s00432-024-06003-x.
[19]Hu W, Zhang K, Han X, et al. Three-dimensional computed tomography angiography and bronchography combined with three-dimensional printing for thoracoscopic pulmonary segmentectomy in stage IA non-small cell lung cancer[J]. J Thorac Dis, 2021, 13(2): 1187-1195. DOI: 10.21037/jtd-21-16.
[20]Ding Y, Feng H, Yang Y, et al. Deep-learning based fast and accurate 3D CT deformable image registration in lung cancer[J]. Med Phys, 2023, 50(11): 6864-6880.DOI: 10.1002/mp.16548.
[21]Mileham KF, Farhangfar CJ. Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non-Small-Cell Lung Cancer?[J]. JCO Oncol Pract, 2023, 19(9): 694-696. DOI: 10.1200/OP.23.00416.
[22]Lanuti M. Commentary: Evolution of the preoperative space: Neoadjuvant targeted therapy in patients with operable non-small cell lung cancer with actionable mutations Surgeon equipoise?[J]. J Thorac Cardiovasc Surg,2023, 165(5): 1694-1695. DOI: 10.1016/j.jtcvs. 2022.12.020.
[23] Zhu Y, Lowe AC. Multiplexed fluorescence in situ hybridization-based detection of circulating tumor cells: A novel liquid-based technology to facilitate accurate and early identification of non-small cell lung cancer patients[J]. Cancer Cytopathol, 2020, 128(8): 518-519. DOI: 10.1002/cncy.22277.
[24]Terrones M, Deben C, Rodrigues-Fortes F, et al. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles[J]. J Transl Med, 2024, 22(1): 234-234. DOI: 10.1186/s12967-024-04988-0.
[25]Wang H, Yuan Y, Qin L, et al. Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models[J]. J Control Release, 2024, 366(3): 746-760. DOI: 10.1016/j.jconrel.2024.01.029.
[26]Veiga M, Kuhweide R, Demaerel V, et al. Labyrinthine enhancement on 3D black blood MR images of the brain as an imaging biomarker for cisplatin ototoxicity in (lung) cancer patients[J]. Neuroradiology, 2021, 63(1): 81-90. DOI: 10.1007/s00234-020-02504-x.
PDF(1761 KB)
